Patrick Malone, MD PhD Profile
Patrick Malone, MD PhD

@patricksmalone

Followers
7K
Following
3K
Media
108
Statuses
1K

physician-scientist turned biotech investor @KdT_Ventures | helping founders build science and tech-driven companies | writing at https://t.co/w5M8DV8u92

DC
Joined March 2011
Don't wanna be here? Send us removal request.
@patricksmalone
Patrick Malone, MD PhD
2 years
on biotech platform strategy. in a new essay, @ElliotHershberg and I riff on biotech platform typology and partnering dynamics. we unpack why many biotechs pivot from external partnerships to internal programs, and why that trend might change in the near future. we start with a
Tweet media one
Tweet media two
Tweet media three
9
24
243
@patricksmalone
Patrick Malone, MD PhD
2 days
RT @JTRobinsonLab: Are we headed toward a technology revolution in therapeutic BCI?. I just wrote this piece about why I believe neurotech….
0
9
0
@patricksmalone
Patrick Malone, MD PhD
2 months
one frustrating aspect of drug development is that the incentives favor “me-too” programs that chase already-validated targets (e.g., TYK2, GLP-1, PD-(L)1). this is in large part due to the fact that patents protect molecules, not the biology behind them. once a target shows.
15
2
62
@patricksmalone
Patrick Malone, MD PhD
3 months
if, for almost any real-world problem, a rational person would rather consult AI than any single human, then AI has crossed the practical threshold we meant when we coined the term AGI.
3
0
20
@patricksmalone
Patrick Malone, MD PhD
3 months
RT @johncumbers: What makes a partnership between pharma and computational drug discovery firms actually work?. This session brings togethe….
0
2
0
@patricksmalone
Patrick Malone, MD PhD
6 months
agreed. and the best way to improve the biotech talent bottleneck is to give promising, emerging management teams the opportunity to prove themselves vs concentrating most of the capital behind a relatively small number of established executives.
@LifeSciVC
Bruce Booth
6 months
The bigger question for me is whether VC money is the rate-limiting factor today for innovation. I don't think it is: 10x more VC money available today than a decade ago. Promising science is also abundant, though translational risk remains high. Shiny new "backable" things.
0
0
18
@patricksmalone
Patrick Malone, MD PhD
7 months
2024 was a huge year for biotech megarounds, with almost 100 startups raising $100M+ financings. shifting so heavily toward these massive deals—and away from smaller, disciplined rounds—is not a good thing for biotech. there are important downsides and knock-on effects for an
Tweet media one
12
14
138
@patricksmalone
Patrick Malone, MD PhD
7 months
love this framing of venture feedback loops as an RL problem. vc is fundamentally a “wicked” learning environment - the connection between cause (the decision to invest) and effect (investment returns) is complex, feedback is delayed or misleading, and patterns that worked in the.
@vvkgopalan
Vivek Gopalan
7 months
venture feedback loops are not that long. if you instrument correctly
Tweet media one
1
2
25
@patricksmalone
Patrick Malone, MD PhD
8 months
🫡 congrats @zavaindar @nanli @AGoulburn.
@zavaindar
Zavain Dar
8 months
Today we're unveiling Dimension II: a $500M fund to support and partner with the leading builders at the vanguard of life sciences and technology. To our entrepreneurs, past present and future: Our work is far from done. LFG.
Tweet media one
Tweet media two
1
0
17
@patricksmalone
Patrick Malone, MD PhD
9 months
awesome opportunity for scientist-entrepreneurs that want to build a neuro startup. join us!.
@PsymedVentures
PsyMed Ventures
9 months
Announcing the Future Neuro Founders Workshop co-hosted by @PsymedVentures and @KdT_Ventures! This virtual workshop is for scientists (PhDs, MDs, postdocs, professors) who want to build a neuroscience startup. Sign up here: 
Tweet media one
0
0
12
@patricksmalone
Patrick Malone, MD PhD
9 months
humbled to announce KdT IV, an oversubscribed $100M+ fund dedicated to supporting early-stage, science-driven companies. at KdT, we believe the most iconic companies of our time are those that leverage scientific breakthroughs to build enduring businesses with significant
Tweet media one
29
13
271
@patricksmalone
Patrick Malone, MD PhD
11 months
it's our second birthday at decoding bio. help us improve!. we're conducting a short survey of our community, only takes a few minutes to complete:
Tweet media one
0
0
7
@patricksmalone
Patrick Malone, MD PhD
11 months
Recursion's clinical trial readouts are not a referendum on the value of AI in drug discovery. some thoughts.
Tweet media one
13
26
174
@patricksmalone
Patrick Malone, MD PhD
11 months
RT @NVIDIAHealth: NVentures backed @Terray_Tx, has unveiled COATI-LDM—a groundbreaking #genAI model for designing small molecules with prec….
0
26
0
@patricksmalone
Patrick Malone, MD PhD
1 year
if you can compress biology, you can predict biology. one way to think about the power of LLMs is as extremely efficient data compression algorithms. at their core, LLMs learn to map high-dimensional input data (e.g., a biological sequence such as a protein) to lower-dimensional
Tweet media one
7
6
85
@patricksmalone
Patrick Malone, MD PhD
1 year
the KdT podcast is back to unpack the first biotech IPO of 2024 - CG Oncology. in The World in a Grain of Sand, we break down an S1 from a recent biotech IPO and share insights on the science, business models, and financials. in this episode, Cain McClary and Phil Grayeski
1
0
8
@patricksmalone
Patrick Malone, MD PhD
1 year
the 2024 edition of the Decoding Bio report is live!. we analyzed many of the most impactful recent papers in AI, biosecurity, cell-based medicines, immunology, and biotech software. from the jump, a core goal of Decoding Bio has been to clearly communicate why these
Tweet media one
1
7
45
@patricksmalone
Patrick Malone, MD PhD
1 year
RT @owl_poster: A primer on molecular dynamics (MD). this covers a lot of the absolute basics of MD in a way that….
Tweet card summary image
owlposting.com
7.8k words, 36 minutes reading time
0
80
0